Stockscreener 앱 받기
105.74
0.12%
0.13
시장 영업 전:
105.70
-0.04
-0.04%
전일 마감가:
$105.61
열려 있는:
$104.46
하루 거래량:
7.02M
Relative Volume:
0.54
시가총액:
$184.18B
수익:
$46.59B
순이익/손실:
$5.41B
주가수익비율:
34.18
EPS:
3.0938
순현금흐름:
$7.38B
1주 성능:
+2.60%
1개월 성능:
+16.53%
6개월 성능:
-3.26%
1년 성능:
-16.21%
1일 변동 폭
$102.89
$106.39
1주일 범위
$102.89
$110.04
52주 변동 폭
$81.97
$137.49
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends - TradingView
Implicity’s Next-Generation ILR ECG Analyzer Earns FDA Clearance - GlobeNewswire Inc.
FRAUD AND MANIPULATION—N.D. Ill.: Abbott did not commit securities fraud over tainted baby formula - VitalLaw.com
Abbott (ABT) Lands Exclusive Rights To FDA Approved Blood Based CRC Test - Yahoo Finance
Freenome went public for $300 million, then scored a huge victory with colorectal cancer test - The Business Journals
Abbott (ABT) Raised Its Profit Forecast. What’s Driving Its Growth? - Yahoo Finance
Federal Judge Dismisses Abbott Shareholder Lawsuit Over 2022 Infant Formula Recall - Law Commentary
Abbott Labs Shakes Investor Suit Over 2022 Infant Formula Recall - Bloomberg Law News
FDA approves Freenome colorectal cancer blood test to be marketed by Abbott - Fierce Biotech
FDA approves Freenome's blood test for colorectal cancer screening - Reuters
Is Abbott Stock Attractive After Its Earnings and Guidance Update? - The Globe and Mail
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S. - BioSpace
Abbott (ABT) Introduces FDA-Approved SimpleScreen CRC for Colore - GuruFocus
Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth - Yahoo Finance
Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & Johnson - The Globe and Mail
Why Is Abbott Laboratories (NYSE:ABT) a Blue-Chip Stock to Watch? - Kalkine Media
Abbott stock trades steady as investors weigh recent earnings and medical device growth - Ad-hoc-news.de
Abbott Laboratories stock trades steadily as diagnostics and medical devices support earnings - Ad-hoc-news.de
PRIVACY ALERT: Abbott Laboratories and Exact Sciences Corporation Under Investigation for Data Breach of Patient Records - Los Angeles Downtown News
Abbott Laboratories (ABT) Could Be 14% Undervalued On Mixed Earnings And Growth Focus - simplywall.st
Abbott defeats shareholder lawsuit over 2022 infant formula recall | Business Information & News | FE - Westlaw Today
Health News Roundup: Abbott Wins Lawsuit, Measles Surge in the US, and More Updates - Devdiscourse
Abbott Beats 'Supersized' Investor Suit Over Formula Recall - Law360
Abbott Wins 7th Circ. Fight Over Baby Formula Warning - Law360
Patient Sues Abbott Labs, Exact Sciences in Data Theft - BankInfoSecurity
Abbott Notches Appellate Win in Bellwether Infant Formula Case - news.bloombergtax.com
Abbott defeats shareholder lawsuit over 2022 infant formula recall - Reuters
Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher - TradingView
FreeStyle Libre 3 Class Action Lawsuit Alleges Abbott Sold Defective Glucose Monitors - AboutLawsuits.com
Medtech Stocks Have Gotten Slammed. Why Abbott, Danaher, 4 More Are Bargains. - Barron's
Abbott Laboratories stock trades steady as diagnostics and medical devices support earnings momentum - AD HOC NEWS
Abbott Laboratories and Exact Sciences Corp Under Investigation for Data Breach of Patient Records - Schubert Jonckheer & Kolbe
Abbott Labs Accused Of Lax Security Over Shinyhunters Hack - Law360
Abbott Stock And 2 Dividend Ideas For Retirement Income - simplywall.st
ISRG vs. ABT: Which MedTech Giant Is the Smarter Investment Now? - TradingView
Abbott Faces Spine Stimulator Lawsuit Brought Jointly by 17 Injured Patients - AboutLawsuits.com
Abbott Laboratories (NYSE:ABT) Faces A Profit Test - Kalkine Media
Daiwa Securities Adjusts Price Target on Abbott Laboratories to $103 From $92, Maintains Neutral Rating - marketscreener.com
Same Industry, Less Money: What Boston Scientific and ResMed Offer That Abbott Laboratories Does Not - Trefis
Abbott Laboratories (ABT) Is Up 12.7% After Revenue Rises But Earnings Shrink In Q2 2026 - simplywall.st
Abbott Laboratories (ABT) Earnings Drew Fresh Attention, Is It Still Below Fair Value? - Yahoo Finance
Abbott Laboratories stock holds gains after strong diagnostics and medical devices momentum - Ad-hoc-news.de
Abbott Laboratories (ABT) Stock Forecasts - Yahoo Finance
Abbott (NYSE:ABT) Faces A Crucial Valuation Test - Kalkine Media
Leerink Partners Adjusts Price Target on Abbott Laboratories to $109 From $106, Maintains Market Perform Rating - marketscreener.com
Cancer Diagnostics Breached At Abbott As 2026 Medtech Cyberattack Run Continues - insights.citeline.com
Abbott (ABT) Stock May Be 32% Undervalued As Legal Overhang Fades - simplywall.st
Abbott Laboratories stock steadies as medical devices and diagnostics underpin growth - Ad-hoc-news.de
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
Patients sue diagnostics company over data breach - Courthouse News
Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories - Yahoo Finance
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.44%
1.59%
자본화:
|
볼륨(24시간):